Designs and develops myoelectric orthotics for individuals with neuromuscular disorders. Produces the MyoPro, a myoelectric-controlled upper limb brace. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 31% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $40.9M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 31 buys and 17 sells. Management buying with its own money is usually read as a good sign.
A loss of $15.6M against $40.9M in annual sales.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, MYO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MYO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.